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Myasthenia gravis (MG) is a neuromuscular disorder leading to ﬂuctuating muscle weakness and fatigue. Rarely, long-term
stabilization is not possible through the use of thymectomy or any known drug therapy. We present our experience with
extracorporeal immunoglobulin (Ig) elimination by immunoadsorption (adsorbers with human Ig antibodies). Acetylcholine
receptor antibodies (AChRAs) were measured during long-term monitoring (4.7±2.9 years; range 1.1–8.0). A total of 474 samples
(232 pairs) were analyzed, and a drop in AChRA levels was observed (P = .025). The clinical status of patients improved and
stabilized. Roughly 6.8% of patients experienced clinically irrelevant side eﬀects. The method of Ig elimination by extracorporeal
immunoadsorption (IA) is a clinical application of the recent biotechnological advances. It oﬀers an eﬀective and safe therapy for
severe MG even when the disease is resistant to standard therapy.
1.Introduction
Myastheniagravis(MG)isanautoimmunedisorderinwhich
weakness is caused by circulating acetylcholine receptor
antibodies (AchRAs) or muscle-speciﬁc kinase antibodies
that block acetylcholine receptors at the postsynaptic neu-
romuscular junction [1]. MG is treated with cholinesterase
inhibitors or immunosuppressive drugs. Surgical removal of
the thymus (thymectomy) may result in permanent remis-
sion or a reduced need for drug therapy. When myasthenia
is serious (myasthenic crisis), plasmapheresis can be used to
removeputativeantibodiesfromthecirculation.Intravenous
immunoglobulins (IVIGs) can also be used to bind the
circulating antibodies [2–5]. Both of these treatments have
relatively short-lived beneﬁts, which are typically measured
in weeks [6]. When some patients are unresponsive to
such therapy while on the maximum-tolerated drug doses
and suﬃcient stabilization is not achieved, they may be
threatened by repeated myasthenic crises. Removal of the
pathogenic agents from the blood may improve the patient’s
condition in these cases. Due to advances in biomedical
technology, adsorbers with speciﬁc aﬃnity for immunoglob-
ulin G (IgG) and the pathogenic antiacetylcholine receptor
antibody of MG [7] have been developed. In severe MG
resistant to other treatments, extracorporeal elimination
(EE) of immunoglobulins by immunoadsorption (IA) has
been used as either a periodic cure [8] or long-term regular
therapy.
In this paper, we review our use of EE of IgGs via
adsorbers containing sheep antibodies against human IgG
as a long-term therapy for severe MG refractory to standard















Figure 1: Our modiﬁcation of immunoadsorption (modiﬁed by Borberg et al. [9, 10]). Vascular access for the extracorporeal circuit is
established via two peripheral veins. Plasma without cellular elements obtained after high-speed centrifugation with a quality separator
(Cobe-Spectra,Denver,USA)isdrawnthroughanadsorbentAdsopakcapsule.Plasmaﬂowiscontinuous.Afterﬁllingtheadsorbentcapsule,
the Adasorb device (Medicap, Ulrichsteinn, Germany) switches automatically to the second adsorbent capsule; the ﬁrst capsule is washed
with glycine, PBS buﬀer, and saline to prepare it for reuse so the procedure can be repeated as necessary. Regeneration solutions are drained
into a waste bag. Clean, washed plasma ﬂows from the column back to the separator where it is mixed with blood elements and returns to
the patient’s peripheral veins. Anticoagulation is maintained by a continuous supply of citrate solution (ACD-A Baxter, Germany), and it is
secured by an initial application of 2500U heparin i.v., subsequent continuous infusion of 50U of heparin/min and gradual dose lowering
such that heparin application ceases in the middle of immunoadsorption.
2. Patientsand Methods
2.1. Extracorporeal Elimination by Immunoadsorption. Here,
we describe our own modiﬁcation of an immunoadsorption
method presented by Borberg et al. [9, 10]. The proce-
dure consists of two main steps: (1) separation of plasma
by continuous centrifugation in a Cobe-Spectra separator
(Cobe, Denver, USA) and (2) subsequent passage of plasma
through a pair of Adsopak 200 adsorbers (Pocard, Moscow,
Russia)placedinanautomaticadsorption-desorptiondevice
(Adasorb, Medicap, Ulrichstein, SRN). The device switches
between two adsorbent capsules and ﬁnally returns plasma
back to the patient. As soon as one of the adsorbent capsules
is full, the automatic device switches to the second capsule;
the ﬁrst capsule is washed and prepared to be used again.
The adsorption cycles are repeated according to the clinical
condition of the patient up to ten times.
The Adsopak 200 adsorption column contains 200mL
of antihuman IgG Sepharose 4FF gel (binding capacity of
10–12mg Ig protein/1mL of adsorbent) and approximately
85mL of phosphate buﬀer (pH 7.4). Polyclonal antibodies
against human Ig bound to Sepharose 4FF are prepared
from sheep serum immunized by human IgG. Adsopak
200Ig columns are intended for use in therapeutic Ig
apheresis procedures for patients requiring rapid reductions
of immunoglobulin concentrations in the plasma. For the
therapeutic scheme, see Figure 1.
2.2. Patients. This prospective observational study was con-
ducted at the 2nd Department of Medicine, Hemapheretic
Center of Charles University, Faculty of Medicine, Hradec
Kralove, Czech Republic. In the Czech Republic, there are
two main centers for the treatment of myasthenia gravis.
Smaller centers are in other teaching hospitals. Presently,
1916 patients are treated at the Myasthenic Center in
Prague. Only six of these patients were in severe condition
despite thymectomy and drug therapy (including corticos-
teroids, immunosuppressive drugs and repeated doses of
immunoglobulins) and could not be stabilized for a longer
period of time. Therefore, these patients were included
in the program of long-term therapy with extracorporeal
eliminationofimmunoglobulins.Basicclinicaldataaregiven
in Table 1.
All patients were women with a mean age of 46 years
(range: 28–65 years). Patients 1 and 2 were successfully
weaned oﬀ of EE therapy after 13 months and are on long-
term immunosuppressive therapy and permanent care at
the Myasthenic Center. Patients 3–6 are on long-term EE
treatment (mean: 6.5 years, range: 5–8 years). Attempts
to reduce therapeutic intensity by weaning oﬀ of EE were
not successful in these patients. Patients 3 and 5 suﬀer
from other diseases (hypertension, ischemic heart disease,
and arthritic symptoms) compensated for by conventional
therapy. Patients 5 and 6 experienced attacks of secondary
depressive syndrome, and patient 4 attempted to commitJournal of Biomedicine and Biotechnology 3
Table 1: Basic clinical data. Number of myasthenic crises experienced requiring artiﬁcial ventilation: + = 1-2, ++ = 2–5, +++ = more than
5. IA = immunotherapy, Mes: Mestinon, M: Medrol, P: Prednison, CC: CellCept, Pr: Prograf.
Patient no. Classiﬁcation (MGFA) Age Sex Myasthen. crises Therapy duration Current condition Current therapy
1 III b 35 F ++ 13 Excellent, IA therapy stopped Mes
2 IV b 33 F + 13 Stabilization, IA therapy stopped Mes
3 IV b 65 F +++ 96 Stabilization Mes, M, CC, IVIG
4 IV b 28 F +++ 76 Stabilization Mes, P, Pr
5 III b 53 F + 79 Stabilization Mes, P, CC, IVIG
6 IV b 60 F ++ 62 Stabilization Mes, P, CC
Table 2: AChRA levels. N = number of patients. Normal AChRA values in our laboratory: 0.00–0.40 nmol/L.
Patient no. AChRA before the procedures (ng/L) AChRA after the procedures (ng/L)
N Mean ± SD Range Median N Mean ± SD Range Median
All 232 12.8 ± 11.4 2.6–99.7 11.2 231 5.46 1.3–57.3 5.5
1 13 51.4 ± 20.9 23.7–99.7 49.6 13 28.0 ± 12.8 13.2–57.3 23.3
21 2 4 . 8 ± 0.6 4.0–6.0 5.0 12 2.4 ± 0.7 1.6–4.0 2.3
34 3 5 . 5 ± 1.2 3.5–9.0 5.4 43 2.3 ± 0.5 1.3–3.5 2.4
4 71 11.9 ± 2.2 7.9–19.0 11.4 70 4.4 ± 0.8 2.8–7.1 4.3
5 58 15.3 ± 3.0 11.2–26.0 15.1 58 6.3 ± 1.0 4.8–9.0 6.3
63 5 7 . 8 ± 2.0 2.6–14.4 7.6 35 2.7 ± 0.4 2.2–4.4 2.6
suicide when in personal crisis. All patients are AChRA-
positive. All underwent thymectomy at the beginning of
therapy with subsequent irradiation. A thymoma was found
in patient 6.
2.3. Ig and AChRA Examination. T h el e v e l so fI g G ,I g A ,
and IgM were determined using the immunonephelometric
method (IMMAGE 800 System, Beckman Coulter, USA).
Determination of autoantibodies against the acetylcholine
receptor was carried out by radio receptor assay for the in
vitro diagnostic quantitative determination of autoantibod-
ies against the acetylcholine receptor in human serum and
plasma (IBL International, Hamburg, Germany).
2.4. Statistics. Statistical calculations were performed with
SYSTAT 8 software. A standard paired t-test (Paired Com-
parison t-Test) was used to evaluate changes before and after
the procedures. The dependence of AChRA values on the
number of procedures was calculated by linear regression
(Simple Linear Regression). Diﬀerences were considered
statistically signiﬁcant when P ≤ .05.
3. Results
3.1. AChRA Levels. To investigate AChRA levels, a total
of 464 samples were collected (232 paired examinations).
Because one measurement was defective, levels in 463
samples were measured. The results are presented in Table 2.
The ﬁrst line summarizes the results for all patients, and the
remainingsixlinespresentevaluationsofindividualpatients.
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Figure 2: AChRA levels—all examinations. Y axis = AChRA level
in ng/L; X axis: Procedure = numeral order of procedures from the
start of therapy.
an average; a paired t-test revealed a signiﬁcance value of
P<. 0001.
Linear correlation analysis showed that a gradual
decrease in AChRA levels occurred after repeated procedures
(P = .025) (Figure 2).
However, an evaluation of individual patients by linear
regression showed that an important drop of AChRA levels
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Figure 3: AChRA levels in patient no. 3. X axis: Procedure =
numeral order of procedures from the start of therapy; Y axis =
AChRA levels in ng/L. Normal value in our laboratory = 0.00–
0.40nmol/L.
patients, AChRA levels did not signiﬁcantly change. As a
positive example (P ≤ .0001), we present patient 3 (see
Figure 3). In this patient, a gradual decrease in AChRA levels
occurred during long-term therapy (i.e., a level of 7.1ng/L
was measured before the ﬁrst IA, and the last measurement
three years later (September 5, 2009) was 4.1ng/L). During
these three years, the patient’s condition was relatively stable
without myasthenic crisis requiring artiﬁcial ventilation.
(Figures 2 and 3, X axis: Procedures = numerical order of
procedures from the start of therapy.)
In the rest of the patients, no gradual drop in AChRA
levels was observed. Levels at the start of the therapy did not
diﬀer in a statistically signiﬁcant manner from either those
further in the course of illness or the last three values.
3.2. Immunoglobulins. Ig levels were examined in all patients
regularly at the same time as AChRA levels. Table 3 shows
that the levels of all three Ig classes signiﬁcantly decreased
after the procedures. This was most obvious for IgG (53.9%
decrease) but was also true for IgM (42.5% decrease) and
IgA (44.7% decrease). Correlation analysis did not ﬁnd
any dependence between the drop in Ig levels and AChRA
levels.
3.3. Adverse Eﬀects. IA is a kind of extracorporeal circula-
tion that brings certain risks. However, the modiﬁcations
presented here allowed it to be a safe and technically
feasible method. Only 6.8% of patients in the 232 pro-
cedures experienced side eﬀects, and none of these were
life-threatening. Patient 3 once experienced aspiration of
excreta during a cough attack and was treated with a short
observation and bed rest. Vasovagal events (symptoms of
neurovegetative lability) were the most common adverse
eﬀects manifested as malaise, weakness, slight and short-
term drop of blood pressure, or other general signs. All were
well controlled by symptomatic therapy (Trendelenburg’s
position, cessation of the procedure and eventual quick
dropping of saline). These reactions were under control in
some tens of seconds or a few minutes at maximum. An
ECG showed sinus bradycardia under a level of 50/min (46
and 48/min) in two cases. This event occurred in patient
6 ,b u to b s e r v a t i o na n ds h o r tb e dr e s tp r o v i d e ds u ﬃcient
treatment.
4. Discussion
Myasthenia gravis is a rather rare neuromuscular disease
of autoimmune origin. However, its course can be severe
or even life-threatening. The annual incidence is from 2 to
4 million cases [11]. Most MG patients can be stabilized
for a long time with either thymectomy or the applica-
tion of symptomatic drugs, corticoids, immunosuppressives,
immunoglobulins, or monoclonal agents. Myasthenic crises
are mostly resolved by plasma exchange. This therapy is
used in the few patients that are diﬃcult to stabilize by
any kind of drug therapy. Advances in biotechnology bring
new knowledge and new methods that can be used in
many branches of medicine [12–16]. One such advance is
extracorporealtherapy,whichcanbeeithernonspeciﬁc(such
as plasma exchange) or speciﬁc (such as IA). This type
of procedure can constitute an important and sometimes
decisive component of MG therapy. IA with regard to med-
ical, technical, and economic demands is indicated in cases
when classical methods fail. We attempted to manage this
situation by extracorporeal elimination of AChRAs present
in the IgG fraction. This was possible by the development
of adsorbers that retain the clinically signiﬁcant Ig com-
ponent from extracorporeal plasma circulation. Adsopak
adsorbers were used. These adsorbers contain antihuman
IgG antibodies with a binding capacity of about 10mg Ig
protein per 1mL of adsorbent. This capacity was suﬃcient
to reduce AChRA levels by an average of 58% after the
procedures.
The patients had diﬀerent initial AChRA levels
that did not correlate with the clinical activity of the
disease [17]( Table 2). In all patients, AChRA levels
signiﬁcantly decreased (by about 57.7% on average)
after the procedures (P<. 0001). With regard to the clinical
eﬀect of therapy, the best result was observed in patient
1. This patient is now maintained on a small dose of
pyridostigmin. She has born a healthy child and enjoys a
happy family life without physical limitations. Presently,
she does not experience any muscular weakness. Similarly,
patient 2 was weaned oﬀ the IA program after 13 months
after stabilization and clinical improvement. This patient is
now on symptomatic medication but experiences residual
weakness of the oropharyngeal muscles of small functional
signiﬁcance. Patients 3–6 are still under a periodic EE
regime. Attempts to wean them oﬀ of treatment were not
successful. In patient 4, procedures are repeated at 4-week
intervals. In patients 4 and 5, the procedures are performedJournal of Biomedicine and Biotechnology 5
Table 3: Immunoglobulins. N: number of patients, SD: standard deviation.
Level (g/L) Before immunoapheresis After immunoapheresis P
N Average SD Range Median N Average SD Range Median
IgG 240 7.93788 2.41842 1.59–14.2 7.25 239 3.65904 1.80996 1.51–12.3 3.21 .000000
IgM 240 0.94921 0.32584 0.18–2.01 0.955 239 0.54782 0.2622 0.15–1.51 0.54 .000000
IgA 240 2.32754 1.02688 0.24–4.51 2.44 239 1.28661 0.70743 0.23–4.07 1.22 .000000
at 3-week intervals. Patient 4 attempted to change to 4-week
intervals after 23 months of EE but shortly thereafter had
to return to 3-week intervals again. In patient 5, the IA
program was initiated at 3-week intervals; after six months,
4-week intervals became suﬃcient. Patients 3 and 5 are on a
periodic regime of EE followed by an IVIG dose performed
during their last year of therapy. This therapy is suﬃcient for
long-term stabilization. However, the clinical condition of
patient 5 worsened during an attempt to wean oﬀ IVIG that
led to a signiﬁcant increase of AChAR levels; therefore, the
IA regime has been continued.
It is well known that MG is more frequent in younger
women and older men [18, 19]. Our group comprised only
women. Due to the small number of patients in our group,
t h i sb i a sw a sd u et om e r ec h a n c e .
We monitored the basic parameters of clinical status
(blood pressure, pulse and breath frequency) in all of our
patients. As IA is one method of extracorporeal circulation,
all basic hematologic and biochemical parameters (blood
count, minerals, creatinin, glycemia and total protein, albu-
min, bilirubin, aminotransferase, and lipoprotein levels; data
not shown) were regularly monitored. The results showed
that clinically signiﬁcant changes did not occur.
The drop in Ig after immunoaphereses was signiﬁcant,
but Ig levels returned to their initial values in the time before
the next procedure. The drop in Ig levels might lead to
increased susceptibility to infections, but we did not observe
such susceptibility. Furthermore, we did not ﬁnd in the
literature data or reports describing higher infection rates
after immunoapheresis for MG [18] or immunoaphereses
performed for other indications (e.g., LDL-apheresis in
familial hypercholesterolemia) [9].
5. Conclusion
The IA method presented here utilizes current results
and recent advances in biotechnology and is indicated in
severe cases of MG when longer-term stabilization cannot
be achieved by another means. The levels of AChRA are
signiﬁcantlyloweraftertheprocedures.ReductionofAChRA
levels can also be observed when patients are evaluated
chronologically (i.e., the levels were higher at the beginning
of follow-up than at the end of monitoring). This method is
medically, technically, and economically demanding. How-
ever, it oﬀers a clinically eﬀective method by which to
improve or stabilize patients with severe MG, even when the
disease is resistant to all standard therapies. In the long run,
this method protects patients against myasthenic crises, and
it is safe with a low occurrence of side-eﬀects.
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